Therapies for Resistant and Recurrent Metastatic Cancer
- November 2017 •
- 338 pages •
- Report ID: 5200531
• The global cancer therapeutics market should reach $172.6 billion by 2022 from $121 billion in 2017 at a compound annual growth rate (CAGR) of 7.4%, from 2017 to 2022.
• Lung cancer as a segment is expected to grow from $15.7 billion in 2017 to $22.6 billion in 2022 at a CAGR of 7.6% for the period 2017-2022.
• Stomach cancer as a segment is expected to grow from $8.2 billion in 2017 to $11.9 billion in 2022 at a CAGR of 7.7% for the period 2017-2022.
Chapter 1: Introduction
Cancer is becoming of increasing importance in society both on an individual and broader level, with governance playing a growing role. Around the globe, cancer incidence has been increasing steadily over the past half-century due to greater longevity, lifestyle (particularly smoking) and environmental influences, as well as improved diagnostics.
Cancer mortality is now in most high-income countries the first- or second-leading cause of death, while in middle- and low-income countries it is slowly increasing its ranking. Not only is cancer having an economic impact due to its increasing contribution to healthcare costs, it also is associated with high indirect costs due to the loss of ability to work.
There will be over 14 million new cases of cancer diagnosed this year, and cancer rates as the second leading cause of death by disease in the world. With over 8 million deaths, resistant and recurrent metastatic disease is the cause of over 90% of these deaths in modern economic societies. By 2030, the global burden is expected to grow to 21.7 million new cancer cases and 13 million cancer deaths simply due to the growth and aging of the population.
A recurrent cancer refers to a cancer that has returned, or recurred, usually after a period of time during which the cancer could not be detected. The cancer may come back to the same place as the original or primary tumor occurred, or to another place in the body.
A metastasis or metastatic cancer is the spread of cancer cells from the place where it first formed to another part of the body. In metastasis, cancer cells break away from the original (primary) tumor, travel through the blood or lymph system, and form a new tumor in other organs or tissues of the body. The new, metastatic tumor is the same type of cancer as the primary tumor. For example, if breast cancer spreads to the lung, the cancer cells in the lung are breast cancer cells, not lung cancer cells.
The latest developments and recent advances in cell biology have provided a greater understanding of mechanisms of how and where the original cancer forms and why metastasis takes place. Nevertheless, metastatic cancers are challenging to treat because they often spread to more than one site, requiring a more complex treatment approach compared with cancer in a single location. Despite the difficulties in treating metastatic cancer, there are currently significant advances available to patients and even more improvements on the horizon. For example, there has been recent progress in the treatment of metastatic lung cancer — specifically, with drugs that target the epidermal growth factor receptor (EGFR) pathway.
It is predicted that further future progress in treating metastatic cancer will almost certainly involve therapies that improve the immune system’s response to metastatic cancer cells, i.e., immunotherapy. There are drugs currently in clinical trials which offer a new and promising means of stimulating the immune system and provide a personalized treatment option.
While these advances in the treatment of metastatic cancer do not mean a cure, it is anticipated they will be able to stabilize a patient for years. The number of treatment options will continue to increase, including combinations of traditional chemotherapy with antibodies and immune-stimulating agents and targeted therapy. The targeting of these treatments will become more effective as diagnostic techniques improve and advances in imaging techniques, such as scans, will enable oncologists to choose appropriate treatments more effectively.
Study Goals and Objectives
The purpose of this report is to initially:
• Examine of the statistics on the incidence and mortality of cancer.
• Present a review of the different forms of resistant and therapeutic metastatic types of cancer.
• Provide an understanding of the mechanisms of resistance and recurrence in metastatic cancer.
• Explain the current treatment options by tumor origin and the treatment strategies for resistant and therapeutic metastatic cancers.
The key objectives of this study are to conduct and provide an analysis of the market value, growth rates, market shares, and market development, as well as examine the market dynamics and market factors influencing the growth and development of the cancer treatment market. This report also looks at the challenges and potential threats facing the industry, and the factors influencing the market shares of the major market suppliers as well as smaller indigenous manufactures in local markets.
Scope of Report
The emphasis of this report is to provide the reader with:
• A review of the different forms of resistant and therapeutic treatments for metastatic cancer, provide an understanding of the mechanisms of resistance and recurrence in metastatic cancer, review the current treatment options by tumor origin, and the treatment strategies for resistant and therapeutic metastatic cancers.
• Provide an analysis and forecast of the revenues for cancer treatments for the global market subdivided by major market subsegments by geographic region and finally by selected country.
• Present a detailed analysis of the global market share, together with a further, more detailed analysis of the market share by geographic region and finally by selected country.
In addition, the analysis provides a:
• Detailed review of the current products, their indications and availability for all the market segments identified.
• Profile of the individual market subsegments within the major market segments analyzed and the distinguishing features of each of the market subsegments.
• Review of the major market opportunities through the recognition of specific high-growth and emerging market opportunities.
• Profile of the leading suppliers of cancer treatments together with related information about specific products.
This study will allow the reader to:
• Gain an insight into the treatment regimens for resistant and therapeutic metastatic cancers and its implications for the patient, the pharmaceutical and biopharmaceutical industries.
• Evaluate the effect of strategic factors such as technology-driven change and industry consolidation for the resistant and therapeutic metastatic cancer market.
• Investigate the current market dynamics that are driving changes in the resistant and therapeutic metastatic cancer market.
• Assess future growth opportunities in the resistant and therapeutic metastatic cancer market.
• Review the main products in each sector and plan a product entry strategy in line with the strengths and weaknesses of the competition.
• Utilize the report to help realize a company’s position in the marketplace and to provide insight into the future of the market and the opportunities that exist.
Methodology and Information Sources
The data collection and forecasting methods used in the preparation of this report are broadly divided into three methods.
Primary Data and Information Gathering
Data on individual product and company sales were gathered through interviews with pharmaceutical and biopharmaceutical companies as well as other relevant sources. These interviews typically include marketing managers, sales managers, distributor managers and owners, sales representatives and managers responsible for research and development (R&D). In addition, interviews were conducted with senior managers among competing companies to determine the strategic direction and focus on the technological advances being made and the sales and marketing policies being adopted.
Representatives from the leading pharmaceutical companies such as Amgen, Bristol-Myers Squibb, Johnson & Johnson, Pfizer Inc, Novartis AG, Eli Lilly, Merck and Co, Takeda Pharmaceutical, Wyeth, Sanofi, AbbVie Inc. and Gilead Sciences, as well as other related sources, were interviewed.
The information was verified and corroborated by other interviews and by secondary sources such as articles in the trade press, press releases, annual reports, online databases and government reports to ensure that the data derived from competitive interviews were accurate.
Secondary Data and Information Gathering
Information was obtained from numerous secondary data sources including statistics provided by the CDC, WHO, FDA, American Cancer Society, Imperial Cancer Research Fund (UK), British Oncology Association, Association of Clinical Research for the Pharmaceutical Industry, European Association for Cancer Research, International Collaborative Cancer Group, The National Cancer Institute, The Institute of Cancer Research (ICR), The North American Association of Central Cancer Registries (NAACCR), The American Joint Committee on Cancer, The European Society for Therapeutic Radiation and Oncology, The German Cancer Society, GLOBOCAN, Prostate Cancer Foundation and more.
While these are believed to be the best secondary sources of data and information about cancer, the estimation of trends from this data is complicated by periodic changes in reporting and classification methods. In addition to the use of corporate annual and quarterly reports, data was obtained from security offering prospectuses, SEC Forms 10-K and 10-Q, and product catalogs and price lists.
This data was used along with other sources of data on company revenues such as investment analysts’ reports, Reuter’s, Dun & Bradstreet, the CorpTech Directory, and personal communications from executives of various companies to develop historical and current estimates of market revenues. Prices used in projections of market revenues are average prices paid by the end-user for the products and are derived from an analysis of list prices and the standard discount structures applied to these list prices.
Market Share Analysis and Market Forecast Prediction
Information and data including estimates of market values, growth rates and market share data were gathered through interviews with the competitors in the market. Great care was taken to avoid bias and untruths through developing a good relationship on the telephone and by using carefully worded questions that cross-verify themselves. The answers from the respondents were cross-verified with answers from other employees and owners of the same company as well as from other manufacturers. Annual reports and the trade press can also confirm that the data collected are in the correct range.
The data gathered were incorporated into proprietary computer forecasting and market share analysis models. The forecast model was used to derive market estimates for future years; it incorporates a rate factor which helps determine the speed with which the market develops, which is similar to that observed in markets for other medical products and is adjusted to match historical data for the market under analysis.
In this report, the geographic regions considered for market analysis include, and only include:
• The United States.
France. Germany. Italy. Spain. The United Kingdom. The Benelux Union (The Netherlands, Belgium and Luxembourg.) Scandinavia. Rest of Europe (ROE).
• South Korea.
Rest of Asia-Pacific (ROAP)
Central and Latin America
• The Middle East.
Resistant and Recurrent Metastatic Cancer, by Type
Cervix Uteri Cancer
All Other Cancers
Chapter 2: Summary and Highlights
The purpose of this chapter is to summarize the key features of resistant and recurrent metastatic cancer, its mechanisms of resistance and recurrence, and the current treatment options and strategies by tumor origin.
According to the latest estimates from the International Agency for Research on Cancer (IARC), there were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 worldwide.
A recurrent cancer refers to a cancer that has come back, usually after a period of time during which the cancer could not be detected. The cancer may come back to the same area as the primary tumor or to another place in the body. For example, a recurrence or recurrent breast cancer is breast cancer that has come back after a period when it couldn’t be detected.
The cancer may come back in the same or opposite breast or chest wall.
A metastasis or metastatic cancer is the spread of cancer cells from the place where they first formed to another part of the body. In metastasis, cancer cells break away from the original tumor, travel through the blood or lymph system, and form a new tumor in other organs or tissues of the body. The new, metastatic tumor is the same type of cancer as the primary tumor. For example, if breast cancer spreads to the lung, the cancer cells in the lung are breast cancer cells, not lung cancer cells.